NewsEvents

Your Yourlocation: Home > Combined use of salmeterol teasone and tiotropium bromide(136310-93-5) in the treatment of lung function in patients with chronic obstructive pulmonary disease

To evaluate the efficacy of salmeterol and tiotropium bromide(136310-93-5) in the treatment of chronic obstructive pulmonary disease. Methods: 88 patients with moderate to severe COPD were randomly divided into three groups, combined with inhalation of salmeterol 50 / 500μg, 2 times a day with a dry powder tiotropium bromide(136310-93-5) 18μg, 1 day; group administered tiotropium dry inhalation powders 18μg, 1 day; administration of salmeterol and fluticasone propionate group inhaled salmeterol xinafoate and fluticasone propionate 50 / 500μg, 2 times a day, before treatment and after the spirometry: compared to the same group before treatment, after treatment group tiotropium, salmeterol and fluticasone propionate group and combined treatment group 1 second forced expiratory volume (FEV1) significantly increased (P <0.05), forced expiratory volume in one second / forced vital capacity, forced expiratory volume in 1 second / predicted value improved than before treatment ( (FEV1 / FVC), the first forced expiratory volume / predicted value was better than that of salmeterolide (P <0.05); the first-second forced expiratory volume, the first-second forced expiratory volume / forced vital capacity (FEV1 / FVC) pine group, statistically significant tiotropium bromide(136310-93-5) group. Conclusion: salmeterol and fluticasone propionate powder for inhalation combined tiotropium powder for inhalation. The efficacy of the treatment of chronic obstructive pulmonary disease is certainly better than a drug treatment alone is worthy of further application and explore.

Address:211#Zhengfeng Building,Huanbaokejiyuan, Gaoxinkaifaqu, Jinan,250100,China TEL:086-531-82375818 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved